AbbVie Inc (ABBV)vsProfound Medical Corp (PROF)
ABBV
AbbVie Inc
$265.36
+0.28%
HEALTHCARE · Cap: $454.36B
PROF
Profound Medical Corp
$5.89
-3.44%
HEALTHCARE · Cap: $214.08M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 337247% more annual revenue ($64.39B vs $19.09M). ABBV leads profitability with a 9.8% profit margin vs -171.6%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PROF
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$265.36
$113.20 premium
Intrinsic value data unavailable for PROF.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -65.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : PROF
The strongest argument for PROF centers on Debt/Equity. Revenue growth of 12.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : PROF
The primary concerns for PROF are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while PROF is a turnaround play — different risk/reward profiles.
PROF carries more volatility with a beta of 0.50 — expect wider price swings.
PROF is growing revenue faster at 12.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 22/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Profound Medical Corp
HEALTHCARE · MEDICAL DEVICES · USA
Profound Medical Corp. The company is headquartered in Mississauga, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?